Rexahn Pharmaceuticals, Inc. Stock Company Profile
Information
15245 Shady Grove Road
Rockville MD 20850
240-268-5300
www.rexahn.com
Description
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companys clinical stage oncology candidates include Archexin that completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; RX-3117, which is in Phase Ib clinical trial for the treatment of patients with solid tumors; and Supinoxin that is in Phase I clinical trial for patients with solid tumors. It is also involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.